NMS after clozapine initiation.
Skarpathiotakis
Mia
M
Westreich
Neal
N
D000284:Administration, Oral; D000293:Adolescent; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000188:drug therapy*; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects*; D003402:Creatine Kinase / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology*; D000077152:Olanzapine; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003402:Creatine Kinase; D003024:Clozapine; D000077152:Olanzapine